Dynavax Technologies (NASDAQ:DVAX) Raised to Buy at StockNews.com

Dynavax Technologies (NASDAQ:DVAX) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Monday.

Several other equities research analysts have also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a report on Friday, February 21st. The Goldman Sachs Group downgraded Dynavax Technologies from a “neutral” rating to a “sell” rating and reduced their price objective for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th. Finally, William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st.

Dynavax Technologies Trading Down 0.1 %

DVAX stock opened at $13.41 on Monday. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of 74.50 and a beta of 1.32. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. Dynavax Technologies has a 1-year low of $9.74 and a 1-year high of $14.05. The business has a 50 day simple moving average of $12.83 and a two-hundred day simple moving average of $12.06.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.05. The firm had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. Research analysts anticipate that Dynavax Technologies will post 0.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new stake in Dynavax Technologies during the fourth quarter valued at approximately $35,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Dynavax Technologies by 37.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 420,325 shares of the biopharmaceutical company’s stock valued at $5,368,000 after buying an additional 113,872 shares during the period. Woodline Partners LP lifted its position in Dynavax Technologies by 2.2% in the fourth quarter. Woodline Partners LP now owns 794,475 shares of the biopharmaceutical company’s stock worth $10,145,000 after buying an additional 17,156 shares during the last quarter. Squarepoint Ops LLC boosted its stake in Dynavax Technologies by 509.3% during the fourth quarter. Squarepoint Ops LLC now owns 124,807 shares of the biopharmaceutical company’s stock worth $1,594,000 after buying an additional 104,325 shares during the period. Finally, Two Sigma Investments LP increased its position in Dynavax Technologies by 9.0% during the fourth quarter. Two Sigma Investments LP now owns 866,356 shares of the biopharmaceutical company’s stock valued at $11,063,000 after acquiring an additional 71,575 shares during the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.